Pasotuxizumab
Based on 1 publication(s) in Google Scholar
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.79%
- No. CAS: 1442657-12-6
- Peso molecular:53.55 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pasotuxizumab
More
Actividad biológica
(scFv-heavy-kappa)-(scFv-heavy-lambda)
Human
CD3E & FOLH1
Pasotuxizumab (0-100 ng/mL approximately, 48 h) leads to activation of CD4+ and CD8+ T cell populations, with EC50s of 3.4-6.7 ng/mL for human cocultures, and 13.7-21.2 ng/mL for cynomolgus monkey cell cocultures[2].
Pasotuxizumab (0-100 ng/mL approximately, 48 h) increases release of interferon-γ, TNF-α, IL-2 and IL-10 in T cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pasotuxizumab (0-100 ng/mL approximately, 48 h) increases release of interferon-γ, TNF-α, IL-2 and IL-10 in T cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:PC-3-huPSMA mouse xenograft model[2]
-
Dosage:0.005-5 mg/kg
-
Administration:i.v., once daily
-
Result:Inhibited tumor growth by 86% (0.005 mg/kg/d) and 99% (5 mg/kg/d).
-
Animal Model:BALB/c mice (PK Assay)[2]
-
Dosage:0.1, 0.3, and 1 mg/kg
-
Administration:i.v. bolus administration or s.c.
-
Result:Pharmacokinetic profile of Rafivirumab.
Dose (mg/kg) AUC (mg h/L) CLmatrix (L/h/kg) T1/2 (h) F (%) i.v. (0.3) 0.93 0.32 9.7 100 s.c. (0.3) 0.17 11 18
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
(scFv-heavy-kappa)-(scFv-heavy-lambda)
-(scFv-heavy-lambda).png)
ELISA, FACS, Functional assay
-
Immobilized PSMA Protein, Human (HEK293, His, HY-P70548A) can bind Pasotuxizumab. The EC50 for this effect is 315.4 ng/mL. -
Immobilized CD3D-CD3E Heterodimer Protein, Human (HEK293, His, HY-P72726) can bind Pasotuxizumab. The EC50 for this effect is 6.564 ng/mL.
Chemical Information
-
No. CAS 1442657-12-6
-
Appearance Liquid
-
Peso molecular 53.55 kDa
-
Color Colorless to light yellow
-
SMILES
[Pasotuxizumab]
-
Synonyms
BAY 2010112; AMG 212; MT112
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureza y Documentación
-
Ficha de datos (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pasotuxizumab Related Classifications
HY-P99802 Related Classifications
Powered by Bioz